摘要
慢性粒细胞白血病(CML)是一种起源于多能造血干细胞的恶性增殖性疾病。它的细胞遗传学特征是有Ph染色体,即t(9;22)(q34;q11)。9号染色体上的abl基因易位到22号染色体的bcr上,形成bcr/abl融合基因。bcr/abl融合基因是慢性粒细胞白血病的分子生物学标志。bcr/abl融合基因表达P210(bcr/abl),P190(bcr/abl)或P230(bcr/abl)蛋白,该蛋白具有异常增高的酪氨酸激酶活性,使造血干细胞发生异常转化而导致CML发生。近几十年来,由于异基因造血干细胞移植、干扰素及联合化疗的临床应用,尤其是bcr/abl酪氨酸激酶抑制剂(STI571)及中药提取物三氧化二砷等的应用,慢性粒细胞白血病的治疗取得了很大进步。
Chronic myeloid leukemia （CML） is a malignant and proliferating disease originating from multipotent hemopoietie stem cell. It is characterized by a specific chromosomal translocation,t （9 ;22 ）, that resulting in a shortened chromosome 22, commonly referred to as the Philadelphia （Ph） chromosome. Ph chromosome is a transloeation of the distal deleted segment of 22q to the distal portion of 9q, forming ber/abl fusion gene. The ber/abl fusion gene express P^210 - （ bcr/abl）, P^190 - （ber/abl） or P^230 - （bcr/abl） protein which has abnormal high activity of tyrosine kinase, abnormally transform the hematopoietic stern cells and result in CML. Over the last years we have gotten great progress in treatment of chronic myeloid leukemia with the use of hemotapoietic stem cell transplantation,interferon - a and combination chemotherapy, especially with the discovery and research of effective drugs, for example imatinih mesylate and sodium arsenite. In this review, we will summarize the recent advance in CML therapy of integrated traditional Chinese and western medicine.
出处
《现代肿瘤医学》
CAS
2009年第4期777-779,共3页
Journal of Modern Oncology
关键词
慢性粒细胞白血病(CML)
中西医结合疗法
BCR/ABL融合基因
chronic myelogenous leukemia （CML）
therapy of integrated traditional Chinese and western medi- cine
bcr/abl fusion gene
